Weitao Bio has completed its Series A and A+ funding rounds, raising over $50 million to advance its in vivo CAR-T therapy pipeline. The funding, led by Zhengxin Valley Capital and Decheng Capital, will support clinical trials and platform expansion for Weitao's lead candidate, GT801, which targets CD19 using T-LNP and mRNA technology. This investment highlights the growing interest in in vivo CAR-T therapies, which aim to simplify the production process by enabling patients' own T cells to generate CAR-T cells internally. The spin-off from Shali Bio allows Weitao to focus on developing its platform for hematological malignancies and autoimmune diseases. The funding round attracted significant venture capital interest, indicating strategic positioning in the CAR-T sector. Weitao's approach seeks to address the challenges of traditional CAR-T therapies, such as high costs and complex manufacturing, by potentially offering a more accessible and scalable solution. The company's progress marks a significant step in the evolution of CAR-T therapies in China, as it enters a phase of parallel development in platform, clinical, and industrial validation.